Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727382 | 1.00 | TDP1 (0.58) | TDP1EPHX2PTPN1MAPTKDM4E | |
| Acetic Acid SCHEMBL31294534 | 0.90 | TDP1 (0.48) | TDP1EPHX2MAPTKDM4EKMT2A | |
| SCHEMBL30542065 | 0.86 | TDP1 (0.52) | TDP1EPHX2PTPN1MAPTKDM4E | |
| SCHEMBL17773091 | 0.84 | TDP1 (0.50) | TDP1EPHX2PTPN1MAPTKDM4E | |
| SCHEMBL20123234 | 0.83 | TDP1 (0.48) | TDP1EPHX2PTPN1MAPTKDM4E | |
| SCHEMBL29421972 | 0.83 | TDP1 (0.54) | TDP1PTPN1MAPTKDM4EKMT2A | |
| SCHEMBL4490735 | 0.83 | TDP1 (0.54) | TDP1PTPN1MAPTKDM4EKMT2A | |
| SCHEMBL8249793 | 0.81 | TDP1 (0.52) | TDP1PTPN1MAPTKDM4EKMT2A | |
| SCHEMBL28274926 | 0.81 | TDP1 (0.52) | TDP1PTPN1MAPTKDM4EKMT2A | |
| SCHEMBL27694686 | 0.81 | TDP1 (0.52) | TDP1PTPN1MAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915333-B1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS BV (NL) | 2015-06-03 | — | — | EP | claimed |
| CN-101243031-B | Process for preparing ubiquinones and ubiquinones | DSM IP ASSETS BV | 2012-05-09 | — | — | CN | claimed |
| EP-2034977-B1 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS BV (NL) | 2011-07-13 | — | — | EP | claimed |
| US-20090325857-A1 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2009-12-31 | — | — | US | claimed |
| US-7601877-B2 | Condensation of a prenol or isoprenol with a hydroquinone or derivative in the presence of 0.005-1.0 mol percent of a Bronsted or Lewis acid catalyst selected from a bismuth, indium or Group 3 chloride, a heteropolyacid, and an NH- or a CH-acidic compound, oxidizing the ubihydroquinone; improved kinetics | DSM IP ASSETS B.V. (NL) | 2009-10-13 | — | — | US | claimed |
| EP-2034977-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSMIP Assets B.V. (NL) | 2009-03-18 | — | — | EP | claimed |
| US-20090041687-A1 | Use of opioid receptor antagonists | DSM IP ASSETS B.V. (NL) | 2009-02-12 | — | — | US | claimed |
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | DSM IPASSETS B.V. (NL) | 2008-11-06 | — | — | US | claimed |
| CN-101243031-A | Process for the preparation of ubihydroquinones and ubiquinones | DSM IP ASSETS BV (NL) | 2008-08-13 | — | — | CN | claimed |
| EP-1926490-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSMIP Assets B.V. (NL) | 2008-06-04 | — | — | EP | claimed |
| EP-1915333-A1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSMIP Assets B.V. (NL) | 2008-04-30 | — | — | EP | claimed |
| WO-2007121916-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2007-11-01 | — | — | WO | claimed |
| WO-2007039058-A2 | USE OF OPIOID RECEPTOR ANTAGONISTS | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | WO | claimed |
| WO-2007017168-A1 | PROCESS FOR THE PREPARATION OF UBIHYDROQUINONES AND UBIQUINONES | DSM IP ASSETS B.V. (NL) | 2007-02-15 | — | — | WO | claimed |
| US-20040151711-A1 | Synthesis of coenzyme Q10, ubiquinone | WEST DANIEL DAVID (US) | 2004-08-05 | — | — | US | claimed |
| US-6686485-B2 | FROM TOBACCO WASTES; THERAPY FOR BRAIN DISORDERS, PREVENT TISSUE DAMAGE | WEST DANIEL DAVID (US) | 2004-02-03 | — | — | US | claimed |
| US-20020156302-A1 | Synthesis of coenzyme Q10, ubiquinone | WEST DANIEL DAVID (US) | 2002-10-24 | — | — | US | claimed |
| JP-54119424-A | — | — | None | — | — | JP | disclosed |
| US-3957836-A | QUINONE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1976-05-18 | — | — | US | disclosed |
| US-3939202-A | MULTISTAGE | TEIKOKU CHEMICAL INDUSTRY CO., LTD. (JA) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156302-A1 | Synthesis of coenzyme Q10, ubiquinone | SQLE, SQOR, NDUFA10 | TDP1 1502/4885EPHX2 1703/4885PTPN1 4591/4885 |
| US-20040151711-A1 | Synthesis of coenzyme Q10, ubiquinone | SQLE, SQOR, NDUFA10 | TDP1 1502/4885EPHX2 1703/4885PTPN1 4591/4885 |
| US-20080275275-A1 | Process for the Preparation of Ubihydroquinones and Ubiquinones | UBE2D3, UBE2L3, UBE2I | TDP1 4456/4885EPHX2 328/4885PTPN1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.